Observational studyIndian journal of pharmacology2026
Association of serum acetaminophen levels with hepatorenal toxicity: A prospective observational study in Tripura, India.
Observational study in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the association between serum acetaminophen levels and hepatorenal function in patients receiving therapeutic doses of acetaminophen over a short period. MATERIALS AND
methodsA prospective observational study was conducted in the department of physical medicine and rehabilitation at a tertiary care hospital in Tripura, India, from August 2021 to July 2022. A total of 109 patients receiving therapeutic doses of acetaminophen were enrolled. Blood samples were collected on day 1 (within 4 h of the first dose) and day 7 of continuous administration. Plasma acetaminophen concentrations were estimated using liquid chromatography-mass spectrometry. Hepatic markers (serum glutamic-oxaloacetic transaminase [SGOT], serum glutamic-pyruvic transaminase [SGPT], total bilirubin, total protein, alkaline phosphatase, albumin, and globulin), and renal markers (serum urea, creatinine, and uric acid) were measured using a fully automated biochemical analyzer.
resultsMean plasma acetaminophen levels increased significantly from 15.09 ± 6.25 μg/ml on day 1 to 17.08 ± 7.34 μg/ml on day 7 (P = 0.001). Mild but statistically significant elevations in SGOT and SGPT (P < 0.05) were observed. Serum urea (P = 0.013) and creatinine (P = 0.031) also showed minor increases, although all values remained within normal reference ranges and were clinically insignificant.
conclusionTherapeutic use of acetaminophen over a short period may lead to subtle hepatorenal changes. While these alterations are not clinically significant, periodic monitoring is advisable in patients requiring prolonged or repeated use. Further studies are warranted to evaluate long-term safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.